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Virus infection may cause transient or long-lasting immune suppression, the
pathogenesis ofwhich has been explained by several possible mechanisms (1-5).
(a) Virus is directly cytopathic for lymphocytes and possibly for antigen-present-
ing cells, macrophages, and astrocytes. (b) Viral antigens on cell surfaces may
enhance cell fusion thereby causing destruction of cells. (c) Soluble or cell-
bound viral antigens may be immunosuppressive. (d) Antiviral antibodies or vir-
ally induced autoantibodies may cause elimination of lymphocytes or other
mononuclear cells (6). (e) Virus-specific cytotoxic T cells may destroy virus-
infected lymphocytes, dendritic cells, macrophages, etc., a possibility for which
circumstantial evidence exists (7).
This study attempts to analyze pathogenetic mechanisms of virally triggered
immune suppression in a mouse model of immune suppression caused by infec-
tion with lymphocytic choriomeningitis virus (LCMV) (2, 4, 5, 8-10). Infection
of mice with LCMV strongly suppressed the T-independent IgM and a strictly
T help-dependent IgG immune response against a second infectious agent (11).
This suppression was observed in immunocompetent adult mice infected with
LCMV, but not in tolerant LCMV carrier mice, or mice infected with LCMV
that were treated with an mAb to eliminate cytotoxic T CD8+ cells. Thus, the
immune suppression in this model is not caused by LCMV itself nor by IFN
induced by it, but rather by the T CD8+-dependent immune response against
LCMV.
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Materials and Methods
BriefDefinitive Report
Mice. Inbred C57BL/6 (H-26), DBA/2 (H-2d), and colony-bred ICR (H-29) nu/nu
and +/+ mice were purchased from the Institut fur Zuchthygiene, Tierspital, University
of Zurich. C57BL/6 nu/nu mice were a gift from the Institut fur biologisch-medizin-
ische, Forschung AG, Ftillinsdorf, Switzerland. Mice were 6-16 wk old.
Virus and Immunization.
￿
The various isolates of LCMV had the following origin: WE
was from Dr. F. Lehmann-Grube, Hamburg, Federal Republic of Germany, and ARM-
STRONG (ARM) was from Dr. M .B.A. Oldstone, Scripps Clinic, La Jolla, CA (5, 10).
LCMV was titrated in vivo intracerebrally or in the footpad to determine the mean infec-
tious dose for 50% (ID) of the mice. Seeds of VSV-NJ (Pringle isolate) have been
obtained from Dr. D. Kolakovsky, University of Geneva, Switzerland, and were grown on
BHK21 cells infected with low multiplicity (12). Mice were usually infected with 0 .2 ml
i.v.
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Determination of Neutralizing Antibody.
￿
The standard neutralization assay was used as
described previously (12). In brief, serial twofold dilutions of heat-inactivated sera were
mixed with equal volumes of virus containing 50-80 plaque-forming units (pfu) in 100
g 1 and incubated at 37*C for 90 min. The dilution of the serum resulting in 50% reduc-
tion of plaques was determined on Vero cell monolayers grown in a 24-well plate (model
3024; Costar, Cambridge, MA). To determine IgG titers, serum was pretreated with 0.05
M 2-ME.
Antibodies.
￿
The rat IgG 2b mAbs YTS 169.4 (anti-Lyt 2) and YTS 191 .1 (anti-L3/T4)
were prepared and used as described elsewhere (13).
Detection of VSV and IFN In Vivo.
￿
Replication of VSV (11) in vivo was determined in
10% homogenates of various organs; IFN levels were measured as described elsewhere
(14) .
Results and Discussion
No Immune Suppression in Mice Tolerant to LCMV or in LCMV-infected Nude
Mice. Mice infected with LCMV-WE showed signs of a long-lasting immune
suppression of antibody responses against a second virus infection. When
C57BL/6 or ICR mice infected with 105 ID of LCMV were subsequently
infected with vesicular stomatitis virus (VSV) 8-30 d later, they made a reduced
(C57BL/6) (Table I) or no (ICR) (Table II) T cell-independent IgM response
and failed to mount a T CD4+ help-dependent anti-VSV IgG response. When
C57BL/6 mice from a LCMV-carrier colony that are tolerant to LCMV (at least
at the T cell level due to transplacental infection with this noncytophathic, or
poorly cytopathic virus before maturation of T cell competence [5, 8, 10]) were
TABLE I
Capacity ofInfected C57BL16 -1-x-1- or nu/nu Mice or of LCMV-carrier
Mice to Produce Neutralizing Anti-VSVAntibodies
* C57BL/6 +/+ (Institut £ür Zuchthygiene; Tierspital Zurich; Switzerland) and C57BL/6
nu/nu mice (Institut fur Medizinische Forschung; Füllinsdorf; Switzerland) were infected
with 105 ID of LCMV-WE 8 d before the inoculation of VSV-NJ. After infection with 105
pfu VSV-NJ, they were bled on days, 4, 8, and 12, thereafter, indicated values are mean
of IgM and IgG titers of three individual serum samples. If not indicated otherwise, mea-
surements did not differ by more than one titration step from the respective mean.
I Mice were injected with rat anti-mouse CD8 mAb (YTS 169.4 [13]), a monoclonal rat anti-
mouse CD4 (YTS 191 .1 [13]) 6, 5, and 4 d before the infection with VSV-IND.
§ Virus carrying offsprings from persistently infected mothers.
Primary
infection* (days
before VSV)
Treatment
Neutralizing
Day 4
IgM IgG
anti-VSV
Day 8
IgG
titers
Day 12
IgG
Exp. I :
C57BL/6 +/+ LCMV(-30 d) - 1,280 <80 160 160
LCMV (-8 d) - 640 <80 <80 <80
- - 2,560 <80 5,120 20,480
Exp. 2:
C57BL/6 +/+ LCMV (-8 d) - 640 <80 <80 <80
- - 10,240 <80 5,120 20,480
LCMV (-8 d) anti-CD8" 2,560 <80 10,240 20,480
- anti-CD81 2,560 <80 5,120 20,480
LCMV carrierl 10,240 <80 2,560 20,480
C57BL/6 nu/nu LCMV - 10,240 <80 <80 <80
- - 10,240 <80 <80 <80LEIST ET AL.
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TABLE II
Capacity ofLCMV-infected ICR -I-/-l- or nu/nu Mice to Produce Neutralizing
Anti-VSVAntibodies: Effects of Treatment with Anti-CD8 or ofAdoptive Transfer
ofLCMV-immune Lymphocytes
ICR +/+
ICRnu/nu
* Experimental procedures are given in Table I.
1 Mice were injected with 1 X 108 spleen lymphocytes from 8-d LCMV-WE or 6-d Vaccinia virus-
immune ICR +/+ mice at the same time as the VSV-NJ infection. LCMV immune lymphocytes
were from mice treated with anti-CD4 (YTS 191.1) on day -1, 1, and 3.
Represents the mean ofthree mice; none of the animals survived day 5.
superinfected with VSV, they made a normal IgM and IgG response. This find-
ing is compatible with previous studies showing more or less normal immune
responses in LCMV-carrier mice to a variety of antigens and infectious agents
(10, 15). Similarly, nude mice infected with LCMV and thereafter inoculated
with VSV mounted a normal IgM response to VSV. Thus, mice connatally tol-
erant to LCMV (carrier mice) and mice that were unable to mount a T cell
response to LCMV (carrier mice and nude mice) were not susceptible to LCMV-
induced immune suppression.
Immune suppression caused by LCMV infection of fully T cell-immunocom-
petent mice could not be caused by IFN induced by LCMV, which could pos-
sibly influence the availability of immunogenic VSV antigens, for the following
reasons. (a) C57BL/6 mice infected with 105 ID of LCMV had IFN-a and -/3 in
the blood on day 2 and 4 (1,280-10,000 U/ml) but IFN had dropped below
detectable levels by day 6 (<20 U/ml), when VSV was usually injected on day
8-10. (b) Nude mice infected with LCMV have IFN-a and -(3 in their serum (16),
but their antibody response to VSV was not suppressed (Table 1) . (c) Normal
mice infected with LCMV, but treated with anti-CD8 antibodies, made normal
anti-VSV IgM or IgG responses despite the fact that they have been shown to
express LCMV-induced levels of IFN-a and -,Q (13) that were comparable with
those found in control mice or mock treated mice. (d) VSV was not found to
replicate in DBA/2 or C57BL/6 mice in other organs than the spinal cord and/
or the brain; at no time could we find plaque-forming VSV in liver, lung, spleen,
or kidneys at 6 h, l, 2, 3, 5, or 7 d after injection in either normal or LCMV-
preinfected mice (data not shown). (e) LCMV infection suppressed IgG respon-
ses to UV-inactivated or formaldehyde-inactivated VSV (11), further indicating
Primary
infection Treatment
Anti-VSV serum
Day 4
IgM IgG
neutralization titers*
Day 8 Day 12
IgG IgM IgG
LCMV - <80 <80 <80 ND <80
- - 2,560 <80 1,920 ND 5,120
LCMV anti-CD8 1,290 <80 640 ND 5,120
LCMV - 1,280 <80 <80 160 <80
- - 2,560 <80 <80 160 <80
LCMV Transfer oll <800 <80
LCMV-immune
lymphocytes(CD4-)
LCMV Transfer of 1,280 <80
Vaccinia-immune
lymphocytes(CD4)1752
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that VSV replication was not necessary and that IFN effects thus could not
explain the results. Therefore, immune suppression apparently is not caused by
LCMV itself or IFN induced by it, but rather by the anti-LCMV immune
response.
Experiments on the Role of Cytotoxic T Cells in LCMV-triggered Immunosuppres-
sion. C57BL/6 (Table I) or ICR (Table II) mice infected with LCMV but then
treated with a rat anti-mouse CD8 mAb (YTS 169.4 ; anti-Lyt 2) (13), before
they were superinfected with VSV, mounted a normal IgM and IgG response to
VSV. This anti-CD8 mAb had been shown earlier to eliminate T CD8+ but not
T CD4+ cells (13) in vivo; and prevented generation of LCMV-specific cytotoxic
T cells. Neither an irrelevant rat mAb (not shown) nor treatment of LCMV-
infected mice with an anti-CD4 antibody relieved the suppression of T CD4+-
independent IgM anti-VSV antibodies; because of the direct effect of the latter
antibody on T CD4+ helper cells (13), its effect on suppression of IgG response
by LCMV infections could not be evaluated. In a second experimental
approach, LCMV-infected ICR nude mice were given LCMV immune spleen
cells from mice pretreated with anti-CD4 antibody (to prevent T helper cells and
IgG antibodies to be generated) on the same day as the VSV infection; IgM anti-
VSV responses measurable on day 4 were reduced when compared with recipi-
ents of Vaccinia virus-immune spleen cells. These experiments suggest that anti-
LCMV T CD8+ cells were involved in causing the observed immune suppression.
Efficient cell-mediated immunity is crucial for the recovery of a host from
many acute viral infections (5, 10); cytotoxic T cells are apparently involved in
this process by destroying infected host cells to prevent virus replication.
Although essential to overcome infections with cytopathic viruses, this immu-
nological effector pathway may cause more cell and tissue damage than neces-
sary in the case of infection with noncytopathic viruses. In these latter infec-
tions, the balance between virus spread and T cell immune response determines
whether either virus elimination (protection) or cell and tissue damage (immu-
nopathology) predominate or whether a virus carrier state (no virus elimination,
no cell and tissue damage) results. Acute hepatitis B, chronic aggressive hepatitis
or hepatitis carrier status in humans (17) and acute LCM disease, chronic LCM-
wasting disease, or LCMV carrier status in mice (5, 8, 10) are examples for these
varying equilibrium conditions between virus and immune response. Similar
considerations may explain some aspects of HIV infection of man, and we
should like to postulate that HIV-induced AIDS, similar to LCMV-induced
immune suppression, may well be an extreme form of an immunopathological
disease where one subpopulation of effector lymphocytes (T CD8+) destroys
virus-infected APC and macrophages or T cell subpopulations (e .g., T CD4+).
There exists evidence for HIV (3), but recently also for LCMV (18), that T
helper cells (T CD4+), but not killer T CD8+ cells, are infected by the virus; also
like HIV (3, 6), LCMV infects, besides many other cells, macrophages and den-
dritic cells very efficiently (5, 10). Whether antiviral T CD8+ cells destroy
infected lymphocytes and mononuclear cells or APC involved in immune
responses in vivo, remains to be established. The report that T CD8+ cells can
control HIV production in vitro (7) and that HIV immune T CD8+ cells destroy
infected macrophages efficiently in vitro (6) are compatible with the idea.LEIST ET AL.
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In conclusion, the presented evidence suggests that virus-specific cytotoxic T
cells may act as suppressor T cells and that immune suppression in LCM is
caused by a T cell-mediated immunopathology. It is conceivable that a similar
pathogenesis may be responsible for immune suppression and AIDS caused by
HIV infection in humans.
Summary
Normal mice infected with 105 infectious doses of lymphocytic choriomenin-
gitis virus (LCMV, WE isolate) generated a reduced or no T cell-independent
IgM and/or T cell-dependent IgG response to a subsequent vesicular stomatitis
virus Indiana (VSV-IND) injection; this transient immune suppression lasted for
weeks to months. Connatally infected LCMV-carrier mice or acutely infected T
cell-deficient nude mice had normal anti-VSV IgM and IgG or IgM responses
respectively. LCMV-infected nude mice transfused with helper cell-depleted
LCMV-specific immune spleen cells were immunosuppressed. Normal mice
infected with LCMV but treated with a rat anti-CD8 mAb (that had been shown
previously to eliminate cytotoxic T cells in vivo) and then infected with VSV
exhibited a normal anti-VSV IgM and IgG response. Since no IFN-a or -(3 was
detected on, or after, day 6 of LCMV infection, neither LCMV alone, nor IFN
induced by it caused the observed immune suppression; the presented evidence
suggests that LCMV-immune CD8+ T cells were responsible for it. It is conceiv-
able that a similar pathogenesis where virus-specific cytotoxic T cells may destroy
virus-infected cells essentially involved in an immune response (APC, T helper
cells, etc.) may be involved in other virally triggered immune suppression or in
AIDS .
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